Neuropathic pain: current definition and review of drug treatment

Murnion, Bridin

doi:10.18773/austprescr.2018.022

Cited by 129 publications

(102 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Approximately 5–10% of the population worldwide suffers from neuropathic pain . This pathological state is caused by a lesion or disease of the somatosensory nervous system, which can result from injury or a medical condition such as cancer, diabetes or autoimmune diseases . The treatment of neuropathic pain is still challenging.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The blockade of CC chemokine receptor type 1 influences the level of nociceptive factors and enhances opioid analgesic potency in a rat model of neuropathic pain

et al. 2020

View full text Add to dashboard Cite

Summary A growing body of evidence has indicated that the release of nociceptive factors, such as interleukins and chemokines, by activated immune and glial cells has crucial significance for neuropathic pain generation and maintenance. Moreover, changes in the production of nociceptive immune factors are associated with low opioid efficacy in the treatment of neuropathy. Recently, it has been suggested that CC chemokine receptor type 1 (CCR1) signaling is important for nociception. Our study provides evidence that the development of hypersensitivity in rats following chronic constriction injury (CCI) of the sciatic nerve is associated with significant up‐regulation of endogenous CCR1 ligands, namely, CCL2, CCL3, CCL4, CCL6, CCL7 and CCL9 in the spinal cord and CCL2, CCL6, CCL7 and CCL9 in dorsal root ganglia (DRG). We showed that single and repeated intrathecal administration of J113863 (an antagonist of CCR1) attenuated mechanical and thermal hypersensitivity. Moreover, repeated administration of a CCR1 antagonist enhanced the analgesic properties of morphine and buprenorphine after CCI. Simultaneously, repeated administration of J113863 reduced the protein levels of IBA‐1 in the spinal cord and MPO and CD4 in the DRG and, as a consequence, the level of pronociceptive factors, such as interleukin‐1β (IL‐1β), IL‐6 and IL‐18. The data obtained provide evidence that CCR1 blockade reduces hypersensitivity and increases opioid‐induced analgesia through the modulation of neuroimmune interactions.

show abstract

Section: Introductionmentioning

confidence: 99%

“…1,2 This pathological state is caused by a lesion or disease of the somatosensory nervous system, which can result from injury or a medical condition such as cancer, diabetes or autoimmune diseases. 1,3 The treatment of neuropathic pain is still challenging. Even strong analgesics such as opioids become inefficient.…”

Section: Introductionmentioning

confidence: 99%

The blockade of CC chemokine receptor type 1 influences the level of nociceptive factors and enhances opioid analgesic potency in a rat model of neuropathic pain

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Furthermore, clinicians undertake regular medication reviews of patients; medications that are not indicated are deprescribed to reduce potential harm to patients. 8,9 The Network has developed management guidelines around gabapentinoid use, including regular review of prescriptions by general practitioners and the clinical director. Off-label use is discouraged.…”

Section: In New South Wales Prisons the Justice Health And Forensicmentioning

confidence: 99%

“…The Network applies a multidisciplinary team approach between primary care, pharmacy, and drug, alcohol and mental health services for these complex patients. Furthermore, clinicians undertake regular medication reviews of patients; medications that are not indicated are deprescribed to reduce potential harm to patients …”

mentioning

confidence: 99%